Multiscan s.r.o.
- Address
- K Nemocnici 1106, 268 31 Horovice, Czechia
Multiscan s.r.o. - Advanced Oncology Research Center
Multiscan s.r.o. is a specialized clinical research facility with extensive expertise in advanced solid tumor malignancies. The center demonstrates particular strength in investigating novel targeted therapies and immunotherapies across multiple cancer types, with a strong focus on precision medicine approaches that address specific molecular alterations and biomarkers.
- Advanced Non-Small Cell Lung Cancer (NSCLC) including KRAS G12C mutations, ALK-positive disease, and PD-L1 high tumors
- Metastatic Castration-Resistant Prostate Cancer (mCRPC) with expertise in hormonal therapies, DNA damage repair deficiencies, and novel combination approaches
- Advanced and Metastatic Breast Cancer, specializing in hormone receptor-positive, HER2-negative disease, including PIK3CA-mutated and CDK4/6 inhibitor combinations
- Metastatic Colorectal Cancer including immunotherapy approaches and cancer cachexia management
The center conducts both early-phase dose escalation studies and pivotal Phase 3 randomized controlled trials, evaluating cutting-edge therapeutic strategies including PARP inhibitors, selective estrogen receptor degraders (SERDs), immune checkpoint inhibitors, and targeted kinase inhibitors. Multiscan s.r.o. maintains robust capabilities in biomarker-driven patient selection and molecular profiling, contributing to the advancement of personalized cancer treatment paradigms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 62 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 61 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1AstraZeneca AB2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Multiscan s.r.o.
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Visugromab in Patients with Cancer-associated Cachexia | CatalYm GmbH | Phase IV | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 62 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 5 | Unknown | 2021-03-17 | 2026-06-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.